Trial of EXenatide in Acute Ischaemic Stroke

NCT03287076 on ClinicalTrials.gov · last registry update 2021-09-14

An unusually large phase 2: 350 participants, more than double the 110 typical for the stage. Its estimated completion date, 4 October 2021, has passed with no update to the record. Primary outcome, as filed: improved neurological outcome. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is approved in the US, but not for cardiovascular disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: UNKNOWN
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: Neuroscience Trials Australia
Sponsor type: Other
Enrollment: 350
Started: 2017-11-23
Primary completion: 2021-10-04 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

improved neurological outcome

Conditions studied

Acute Ischemic Stroke

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.